新诊断胶质母细胞瘤患者接受5次立体定向放射外科联合5毫米边缘并同步替莫唑胺治疗的I/II期试验:主要结局
该I/II期试验采用3+3设计,在4个递增剂量水平(25、30、35、40 Gy)下,对新诊断胶质母细胞瘤患者进行5次立体定向放射外科(SRS)联合5毫米边缘并同步替莫唑胺治疗,以确定最大耐受剂量(MTD)。2010至2015年共入组30例患者,中位年龄66岁。按方案MTD为40 Gy分5次;晚期不良放射效应(ARE)仅限于1-2级,未对生存期产生统计学影响。
要点
- 按方案MTD为40 Gy分5次,联合5毫米边缘和同步替莫唑胺。
- 剂量限制性毒性(DLT)发生在2例患者中,均为40 Gy剂量组。
- 晚期1-2级ARE发生于8例患者,中位时间7.6个月,无3-5级ARE。
核心结论
- 按方案5次SRS联合5毫米边缘并同步替莫唑胺的MTD为40 Gy分5次。
- ARE仅限于1-2级,且未对生存期产生统计学影响。
研究设计与样本
- I/II期试验,采用3+3设计,4个递增剂量水平:25、30、35、40 Gy。
- 入组新诊断胶质母细胞瘤成人患者,接受5天SRS联合5毫米边缘并同步替莫唑胺治疗。
- 2010至2015年共入组30例患者,中位年龄66岁(范围51-86岁)。
- 中位靶体积为60 cm3(范围14.7-137.3 cm3)。
- 剂量限制性毒性定义为常见不良事件评价标准3-5级急性或晚期中枢神经系统毒性,包括不良放射效应(ARE)。
主要发现
- DLT发生于2例患者:1例为治疗后脑水肿和3周时疾病进展(4级,40 Gy剂量);另1例在SRS后1.5周死于术后并发症(5级,40 Gy剂量)。
- 晚期1-2级ARE发生于8例患者,中位时间7.6个月(范围3.2-12.6个月);无3-5级ARE发生。
- 中位随访13.8个月(范围1.7-64.4个月),中位无进展生存期为8.2个月(95%CI:4.6-10.5),中位总生存期为14.8个月(95%CI:10.9-19.9)。
- O6-甲基鸟嘌呤-DNA甲基转移酶高甲基化患者的中位生存期为19.9个月(95%CI:10.5-33.5),无/未知高甲基化患者为11.3个月(95%CI:8.9-17.6)(P=0.03)。
- 发生晚期ARE患者的中位生存期为27.2个月(95%CI:11.2-48.3),未发生ARE患者为11.7个月(95%CI:8.9-17.6)(P=0.08)。
关键数值与推荐
- 按方案MTD为40 Gy分5次。
- DLT定义为常见不良事件评价标准3-5级急性或晚期中枢神经系统毒性,包括ARE。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM). METHODS: We enrolled adult patients with newly diagnosed glioblastoma to 5 days of SRS in a 3 + 3 design on 4 escalating dose levels: 25, 30, 35, and 40 Gy. Dose limiting toxicity (DLT) was defined as Common Terminology Criteria for Adverse Events grades 3-5 acute or late CNS toxicity, including adverse radiation effect (ARE), the imaging correlate of radiation necrosis. RESULTS: From 2010 to 2015, thirty patients were enrolled. The median age was 66 years (range, 51-86 y). The median target volume was 60 cm3 (range, 14.7-137.3 cm3). DLT occurred in 2 patients: one for posttreatment cerebral edema and progressive disease at 3 weeks (grade 4, dose 40 Gy); another patient died 1.5 weeks following SRS from postoperative complications (grade 5, dose 40 Gy). Late grades 1-2 ARE occurred in 8 patients at a median of 7.6 months (range 3.2-12.6 mo). No grades 3-5 ARE occurred. With a median follow-up of 13.8 months (range 1.7-64.4 mo), the median survival times were: progression-free survival, 8.2 months (95% CI: 4.6-10.5); overall survival, 14.8 months (95% CI: 10.9-19.9); O6-methylguanine-DNA methyltransferase hypermethylated, 19.9 months (95% CI: 10.5-33.5) versus 11.3 months (95% CI: 8.9-17.6) for no/unknown hypermethylation (P = 0.03), and 27.2 months (95% CI: 11.2-48.3) if late ARE occurred versus 11.7 months (95% CI: 8.9-17.6) for no ARE (P = 0.08). CONCLUSIONS: The per-protocol MTD of 5-fraction SRS with 5-mm margins with concurrent temozolomide was 40 Gy in 5 fractions. ARE was limited to grades 1-2 and did not statistically impact survival.
引用
- Azoulay M, Chang SD, Gibbs IC, et al. A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. Neuro Oncol. 2020. PMID: 32002547. doi:10.1093/neuonc/noaa019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。